Climb Bio Inc
For the period ended Sep 30, 2024. Filed Nov 12, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 12, 2024
CLYM$11.01+7.0%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
| Incorporated by Reference | |||||
|---|---|---|---|---|---|
| Exhibit Number | Description of Exhibit | Form | File No. | Exhibit | Filing Date |
| 2.1 | Agreement and Plan of Merger and Reorganization, dated as of April 10, 2024, by and among Eliem Therapeutics, Inc., Tango Merger Sub, Inc., Tenet Medicines, Inc. and, solely in his capacity as the Company Equityholder Representative, Stephen Thomas. | 8-K | 001-40708 | 2.1 | 4/11/2024 |
| 3.1* | Amended and Restated Certificate of Incorporation, as amended, of the Registrant | ||||
| 3.2 | Amended and Restated Bylaws of the Registrant | 8-K | 001-40708 | 3.2 | 10/2/2024 |
| 4.2 | Form of common stock certificate of the Registrant | S-1 | 333-257980 | 4.1 | 8/2/2021 |
| 4.3 | Amended and Restated Investors Rights Agreement, dated May 21, 2021, by and among the Registrant and the investors listed on Schedule A thereto | S-1 | 333-257980 | 10.1 | 7/16/2021 |
| 10.1* | Consulting Agreement, dated June 27, 2024, between the Registrant and Stephen Thomas. | ||||
| 10.2* | Amendment to Consulting Agreement, dated November 1, 2024, between Registrant and Stephen Thomas | ||||
| 10.3 | Offer Letter, dated July 31, 2024 between the Registrant and Brett Kaplan, M.D. | 8-K | 001-40708 | 10.1 | 8/26/2024 |
| 10.4 | Settlement Agreement, dated August 23, 2024, between Eliem Therapeutics, (UK) Limited and Valerie Morisset, Ph.D. | 8-K | 001-40708 | 10.1 | 8/27/2024 |
| 31.1* | Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | ||||
| 31.2* | Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | ||||
| 32.1* | Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | ||||
| 32.2* | Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | ||||
| 101.INS | Inline XBRL Instance Document – the instance document does not appear in the Interactive File because XBRL tags are embedded within the Inline XBRL document. | ||||
| 101.SCH | Inline XBRL Taxonomy Extension Scheme Document | ||||
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document | ||||
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document | ||||
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document | ||||
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document | ||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | ||||
- Filed herewith.
.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.